MOG and ocular melanoma: Notably, a single therapeutic intradermal i.d. injection of OM-MOG is sufficient to reduce inflammatory spinal cord lesions in mice with active EAE, suggesting that peripheral activation of Ly6ChiCCR2+ myeloid progenitor cells might be a promising way forward to achieve selective immunotherapy in autoimmune diseases affecting the human CNS.